This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
ramipril, using the life table method. The primary analysis was to evaluate the net cost-effectiveness with 5-, 10-, 15and 20-year (lifetime) ramipril treatment assuming continued benefit.
Outcomes assessed in the review
The outcomes assessed in the review were: the annual probability of death for men in the UK and in the different risk groups; the relative reduction in mortality by ramipril; and the reduction in myocardial infarction, revascularisation and stroke.
Study designs and other criteria for inclusion in the review
The effectiveness of ramipril was based on the HOPE trial, a multi-centre randomised placebo-controlled trial. To select pretreatment cardiovascular risks required to evaluate the cost-effectiveness in other groups, trials of primary prevention (WOSCOPS) and in high-risk patients (ISIS-2) were used.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness data were obtained from a single study (the HOPE trial). Other published sources were used to build the model (7 studies).
Methods of combining primary studies
A narrative method was used to combine the studies.
Investigation of differences between primary studies
Results of the review
The base-case group (medium risk, based on the HOPE trial) had an annual mortality rate 1.31 times greater than that of men aged 56 to 69 years in the UK. The low-risk group had a mortality rate of 0.54 and the high-risk group a mortality rate of 2.4.
With ramipril, the relative risk of all-cause mortality was 0.84. It was assumed to be the same in all cohorts.
The rate of myocardial infarction was reduced from 12 to 9.8%, (p=0.0005), after taking ramipril. The rate of revascularisation decreased from 18.4 to 16.0%, (p=0.0013). The rate of stroke changed from 4.8 to 3.3%, (p=0.0002).
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Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
The authors assumed that the benefit of ramipril was accrued during the whole time horizon taken and was constant for life, and that ramipril was equally effective in all patients. The ratio of the mortality risk that was applied to the UK population, to calculate each cohort life expectancy, was assumed to remain constant for life.
Measure of benefits used in the economic analysis
The measure of benefit was the life-years gained (LYG). These were derived from the decision model. It was unclear whether future life-years were discounted.
Direct costs
The authors reported both undiscounted results and those using a 6% discount rate. The unit costs and the quantities of resources used were not presented separately. The perspective adopted was that of the UK health care provider. The costs estimated were for drug treatment, myocardial infarctions, revascularisation procedures (angioplasty and bypass surgery), and other coronary disease-related admissions for unstable angina and heart failure. The costs and quantities were estimated through modelling. The quantity and cost data was obtained from local data published from 1999 to 2000. The price year was 1999 to 2000. Although additional physician consultation, pharmacy handling costs and the need for extra serum electrolyte measurement may raise the total drug costs, the authors appear to have excluded these since their effect is small relative to the drug price.
Statistical analysis of costs
The costs were treated deterministically and were derived by modelling.
Indirect Costs
The indirect costs were not included.
Currency
UK pounds sterling ().
Sensitivity analysis
Different one-way sensitivity analyses were carried out. These varied the drug treatment prices and cost-savings (arising from reductions in events) between 50 and 200% of the baseline values, based on authors' assumptions.
Estimated benefits used in the economic analysis
In the base-case analysis of the medium-risk group and a total eligible population of at least 3,000,000 patients, the model predicted 12,000 lives gained per year. For the ischaemic heart disease population, estimated at 1,400,000 eligible patients, 5,600 lives were gained per year. The corresponding figures were 600,000 (eligible population) and 2,400 (lives saved) for stroke, 1,700,000 (eligible population) and 6,800 (lives saved) for diabetes, and 1,000,000 (eligible population) and 4,000 (lives saved) for peripheral vascular disease. Side effects were not considered.
Cost results
In the base-case analysis of the medium-risk group and a total eligible population of at least 3,000,000 patients, the model predicted an increase in NHS drug costs of 500 million. However, the total net costs would increase by an additional 360 million/year due to reductions in health care use. The costs of side effects were not considered.
Synthesis of costs and benefits
An incremental cost-effectiveness ratio was calculated to combine the costs and benefits of ramipril relative to placebo.
In the medium-risk group, the 5-year undiscounted cost-effectiveness was 13,600 per LYG. With lifetime therapy (20-year horizon), the cost per LYG decreased to 1,900.
Applying a 6% discount rate, the corresponding figures were 14,700 (5 years) and 2,800 (lifetime treatment), respectively.
The cost-effectiveness figures were 36,000 (5 years) and 5,300 (lifetime therapy) per LYG in the low-risk group, and 4,000 (5 years) and 100 (lifetime therapy) per LYG in the high-risk group.
In the highest risk sub-group (7% annual mortality), the cost-effectiveness was 1,300 per LYG at 5 years, and -900 per LYG over 20 years (cost-saving).
Besides pretreatment risk, the drug cost was the other major cost-effectiveness determinant. For example, varying the drug costs between 50 and 200% of the initial values altered the lifetime cost-effectiveness from 400 to 4,900 per LYG in the medium-risk group (HOPE study population). For changing the cost-savings in the same range, the lifetime costeffectiveness varied from 900 to 2,500 per LYG.
When the authors changed the assumption of sustained ramipril benefit and limited it to 5 years in the medium-risk group, the cost-effectiveness over 5 to 20 years remained stable at 12,000 and 13,000 per LYG.
Some cost categories relevant to the perspective adopted were excluded, more specifically, the costs of additional physician consultation, pharmacy handling and extra serum electrolytes. The authors stated that these costs had a small effect compared with the drug price. The savings excluded, which may underestimate the cost-effectiveness of ramipril, were the reduction of diabetes and overt nephropathy incidence. The costs and the quantities were not reported separately.
It was unclear from the paper whether the authors used a fixed incidence of events requiring resource use (e.g. myocardial infarction in the different risk groups), as the incidence of events was expected to be different among subgroups. Resource use data were taken from HOPE trial and from literature on current UK practice. A sensitivity analysis on the quantities does not seem to have been performed. However, a sensitivity analysis was conducted on the total costs. No statistical analysis of the costs or quantities was performed. The prices were taken from published sources and the cost date was unclear.
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